FindTrial
Sign In

Exploration of the imaging features of diffuse midline glioma (with H3 K27 changes) and its differential diagnosis

Exploration of the imaging features of diffuse midline glioma (with H3 K27 changes) and its differential diagnosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077926
Enrollment
Unknown
Registered
2023-11-23
Start date
2023-06-21
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Observation group:None

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged 3 to 70 years with clinically proven "diffuse midline glioma with H3 K27 changes" who have undergone MRI enhancement prior to surgery or biopsy

Exclusion criteria

Exclusion criteria: (1) Those without further pathological verification of the molecular typing of the tumour. (2) Poor image quality after scanning, which prevents MRI reading. (3) ADC maps that do not allow accurate measurement of relevant parameters, or baseline clutter in 1H-MRS spectrograms, the corresponding quantitative parameter measurement was discarded for this patient.

Design outcomes

Primary

MeasureTime frame
Enhancement method, rADCmin, rADC peritumoral, rADCmean;—

Secondary

MeasureTime frame
CT value, Cho/NAA, Cho/Cr, Lac peak, Lip peak, tumor diameter;—

Countries

China

Contacts

Public ContactYang Qihua

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

85536516@qq.com+86 180 0229 9992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026